Food and Drug Administration has identified certain bulk drug substances used in compounding as substances that may present significant safety risks, and BPC-157 has been discussed in that regulatory context
In individuals with pre-existing gastrointestinal conditions such as inflammatory bowel disease, coeliac disease, or irritable bowel syndrome, introducing any new supplement may temporarily affect bowel habits as the digestive system adapts
It helps protect the body from free radicals, which can cause oxidative stress and damage to cells and tissues
CJC-1295 Ipamorelin FDA status in 2026: approval, compounding, Category 2 safety concerns, and research-only availability
Nat Rev Genet 10:155159
Dong, B., Zhou, G., Lin, Y., Yu, C., Wang, J., Sun, C., et al., Appl